Thus far, our data have suggested miR-146a prevents colonic inflammation and CRC development by suppressing both myeloid cell induction of IL-17-producing cells and responsiveness of IECs to IL-17 by targeting RIPK2 in myeloid cells and TRAF6 in IECs, respectively. Here, IL17A is linked to colorectal carcinoma.